Cited by 119Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and TreatmentsDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis

Leuschner, Maria, Güldütuna, Sükrettin, You, Tiangeng, Hübner, Klaus, Bhatti, Susan, Leuschner, Ulrich·1996·Journal of Hepatology

DOI 10.1016/s0168-8278(96)80327-8

Open this paper in CoChat — free account

Abstract

Background Ursodeoxycholic acid probably is not able to cure primary biliary cirrhosis. Therefore in this study ursodeoxycholic acid was administered together with prednisolone, since monotherapy with glucocorticoids has been shown to have some positive effects. Methods Thirty patients with primary biliary cirrhosis (stages I-III) were entered into the study. Fifteen were treated with ursodeoxycholic acid 10 mg.kg-1.day-1 and placebo (group A), 15 with ursodeoxycholic acid and 10 mg prednisolone (group B) for 9 months. Apart from the usual laboratory examinations, liver biopsies were taken from 29 patients before and after therapy. Results Liver enzymes decreased significantly compared to the initial values in both groups (p < 0.001), but in group B cholestasis-indicating enzymes and the immunoglobulins G and A improved more rapidly. Between both groups the differences for AP, GGT, IgG, IgA and gamma-globulins were significant (p < 0.05), but only for short terms. In group B, liver histology improved significantly (p < 0.003), which correlated with the decrease of IgG. Ursodeoxycholic acid became the predominant bile acid in the serum. Toxic bile acids did not increase. Bone densitometry revealed a slight deterioration of preexisting osteoporosis in one patient. Conclusions Although combination therapy with ursodeoxycholic acid and prednisolone was not superior to monotherapy with ursodeoxycholic acid with regard to liver function tests, it had a highly beneficial influence on liver histology. In our previous trials with monotherapy histology remained unchanged. An early decrease in IgG during combination therapy seems to be an indicator of an amelioration of liver histology.

Integrity signals

Registry

Crossref · 10.1016/s0168-8278(96)80327-8

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PRACTICAL STEREOLOGICAL METHODS FOR MORPHOMETRIC CYTOLOGY
Weibel, E. R., Kistler, G., & Scherle, W. F. (1966) · The Journal of Cell Biology · doi:10.1083/jcb.30.1.23 · Cited by 1,838
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial
Leuschner, U., Fischer, H., Kurtz, W., Güldütuna, S., Hübner, K., Hellstern, A., Gatzen, M., & Leuschner, M. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)91698-3 · Cited by 352
Self-citation
A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
COMBES, B., Carithers, R. L., Maddrey, W. C., Lin, D., McDonald, M. F., Wheeler, D. E., Eigenbrodt, E. H., Muñoz, S. J., Rubin, R., Garcia-Tsao, G., et al. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 303
A controlled trial of prednisolone treatment in primary biliary cirrhosis
Mitchison, H. C., Palmer, J. M., Bassendine, M. F., Watson, A. J., Record, C. O., & James, O. (1992) · Journal of Hepatology · doi:10.1016/0168-8278(92)90065-w · Cited by 199
A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone loss
Mitchison, H. C., Bassendine, M. F., Malcolm, A. J., Watson, A. J., Record, C. O., & James, O. (1989) · Hepatology · doi:10.1002/hep.1840100405 · Cited by 151
Serum bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid therapy
Poupon, R. E., Chrétien, Y., Poupon, R. Y., & Paumgartner, G. (1993) · Hepatology · doi:10.1002/hep.1840170412 · Cited by 119
Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis
Stiehl, A., Rudolph, G., Raedsch, R., Möller, B., Hopf, U., Lotterer, E., Bircher, J., Fölsch, U. R., Klaus, J., Endele, R., et al. (1990) · Hepatology · doi:10.1002/hep.1840120308 · Cited by 115

Show all 33 references

Research works printed but not linked: 3

David, 1985, Die Wirkung von Ursodesoxycholsäure bei chronischen Leberkrankheiten, Eine Pilotstudie (abstr.). Z Gastroenterol, 23, 420
Schaffner, 1991, Ursodeoxycholic acid (U) + colchicine (C) for treatment of primary biliary cirrhosis (PBC) (abstr.), Hepatology, 14, 62A
Kaplan, 1992, The therapeutic effects of ursodiol and methotrexate are additive and well tolerated in primary biliary cirrhosis (abstr.), Hepatology, 16, 92A

Sorted by citations

EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Primary Biliary Cirrhosis
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241
Primary biliary cirrhosis
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome
Corpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’
Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00092-7 · Cited by 428
Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration
Geier, A., Wagner, M., Dietrich, C. G., & Trauner, M. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.04.014 · Cited by 314
Primary biliary cirrhosis
Talwalkar, J. A., & Lindor, K. D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13808-1 · Cited by 300
Ursodeoxycholic acid for primary biliary cirrhosis
Rudić, J. S., Poropat, G., Krstic, M. N., Bjelaković, G., & Gluud, C. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551.pub3 · Cited by 277
Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial
Leuschner, M., Maier, K., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H. H., Ackermann, H., Happ, J., & Leuschner, U. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70351-3 · Cited by 247
Self-citation
Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three‐year randomized trial†
Rautiainen, H., Kärkkäinen, P., Karvonen, A., Nurmi, H., Pikkarainen, P., Nuutinen, H., & Färkkilä, M. (2005) · Hepatology · doi:10.1002/hep.20646 · Cited by 222
Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome
Chazouillères, O., Wendum, D., Serfaty, L., Rosmorduc, O., & Poupon, R. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.017 · Cited by 194
Primary biliary cirrhosis
Hohenester, S. D., Elferink, R. P. J. O., & Beuers, U. H. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0164-5 · Cited by 178
Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases
Trauner, M., & Graziadei (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00596.x · Cited by 153
Nuclear receptors as therapeutic targets in cholestatic liver diseases
Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00030.x · Cited by 146
Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells
Arenas, F., Hervías, I., Úriz, M., Joplin, R., Prìeto, J., & Medina, J. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33156 · Cited by 116
Targeting FXR in Cholestasis
Keitel, V., Dröge, C., & Häussinger, D. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_231 · Cited by 106
Autoimmune hepatitis and its variant syndromes
BEN-ARI, Z., & CZAJA, A. J. (2001) · Gut · doi:10.1136/gut.49.4.589 · Cited by 102
Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity
Zollner, G., Wagner, M., & Trauner, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.03.005 · Cited by 91
Use of ursodeoxycholic acid in liver diseases
Kumar, D., & Tandon, R. K. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02376.x · Cited by 88
Clinical Significance of Serum Bilirubin Levels Under Ursodeoxycholic Acid Therapy in Patients With Primary Biliary Cirrhosis
Bonnand, A.-M., Heathcote, J., Lindor, K. D., & Poupon, R. E. (1999) · Hepatology · doi:10.1002/hep.510290140 · Cited by 85
Ursodeoxycholic acid for primary biliary cirrhosis
Gluud, C. N., & Christensen, E. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551 · Cited by 85
Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study
Wolfhagen, F. H. J., van Hoogstraten, H. J. F., van Buuren, H. R., Henegouwen, G. P. V. B., ten Kate, F. J. W., Hop, W. C. J., van der Hoek, E. W., Kerbert-Dreteler, M. J., van Lijf, H. H., den Ouden, J. W., et al. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80254-7 · Cited by 83
Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis
Jun, I. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.04.001 · Cited by 79
Ursodeoxycholic acid for primary biliary cirrhosis
Gong, Y., Huang, Z. B., Christensen, E., & Gluud, C. N. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551.pub2 · Cited by 81
The Overlap Syndromes of Autoimmune Hepatitis
Czaja, A. J. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2367-1 · Cited by 76
Immunological abnormalities in patients with primary biliary cholangitis
Ma, W., & Chen, D. (2019) · Clinical Science · doi:10.1042/cs20181123 · Cited by 76
Drug Therapies for Chronic Cholestatic Liver Diseases
Wagner, M., & Fickert, P. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021059 · Cited by 75
Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease
Ormarsdóttir, S., Ljunggren, Ö., Mallmin, H., Brahm, H., & Lööf, L. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80167-6 · Cited by 61
The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone
Koch, A., Brahm, J., Antezana, C., Smok, G., & Cumsille, M. A. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80294-2 · Cited by 57
Pharmacological interventions for primary biliary cholangitis
Saffioti, F., Gurusamy, K. S., Eusebi, L. H., Tsochatzis, E. A., Davidson, B. R., & Thorburn, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011648.pub2 · Cited by 54
Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone
Rabahi, N., Chrétien, Y., Gaouar, F., Wendum, D., Serfaty, L., Chazouillères, O., Corpechot, C., & Poupon, R. Y. (2010) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2010.02.004 · Cited by 53
Old and new treatments for primary biliary cholangitis
Chascsa, D. M. H., Carey, E. J., & Lindor, K. D. (2017) · Liver International · doi:10.1111/liv.13294 · Cited by 50
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 50
Transcriptional regulation of hepatobiliary transport systems in health and disease: Implications for a rationale approach to the treatment of intrahepatic cholestasis
Wagner, M., & Trauner, M. (2005) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32071-x · Cited by 47
PRIMARY BILIARY CIRRHOSIS AND PRIMARY SCLEROSING CHOLANGITIS
Angulo, P., & Lindor, K. D. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70084-2 · Cited by 46
Aberrant expression of cytokeratin 7 as a histological marker of progression in primary biliary cirrhosis
Yabushita, K., Yamamoto, K., Ibuki, N., Okano, N., Matsumura, S., Okamoto, R., Shimada, N., & Tsuji, T. (2001) · Liver International · doi:10.1034/j.1600-0676.2001.210108.x · Cited by 45
Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: A foray across diagnostic boundaries
Czaja, A. J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.037 · Cited by 40
Medical Treatment of Cholestatic Liver Disease
Paumgartner, G., & Pusl, T. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.013 · Cited by 38
Advances in pharmacotherapy for primary biliary cirrhosis
Mousa, H. S., Lleò, A., Invernizzi, P., Bowlus, C. L., & Gershwin, M. E. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.998650 · Cited by 36
Primary biliary cirrhosis in adults
Momah, N., & Lindor, K. D. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.888950 · Cited by 33
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach
Mousa, H. S., Carbone, M., Malinverno, F., Ronca, V., Gershwin, M. E., & Invernizzi, P. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.003 · Cited by 33
Current management of primary biliary cirrhosis and primary sclerosing cholangitis
Levy, C., & Lindor, K. D. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00006-0 · Cited by 32
Medical Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
Holtmeier, J., & Leuschner, U. (2001) · Digestion · doi:10.1159/000048854 · Cited by 33
Self-citation
FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver
Rosales, R., Romero, M. R., Vaquero, J., Monte, M. J., Requena, P., Martínez‐Augustin, O., de Medina, F. S., & Marı́n, J. J. G. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.001 · Cited by 30
Natural history and management of primary biliary cirrhosis
Kumagi, T., & Al‐Harthy, N. (2012) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s25998 · Cited by 30
Glucocorticosteroids for primary biliary cirrhosis.
Prince, M., Christensen, E., & Gluud, C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003778.pub2 · Cited by 28
Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid
van Hooff, M. C., Werner, E., & van der Meer, A. J. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.030 · Cited by 32
Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors
Marschall, H., Wagner, M., Zollner, G., & Trauner, M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060133c · Cited by 27
Treatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents
Silveira, M. G., & Lindor, K. D. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.008 · Cited by 27
Medical Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
Rust, C., & Beuers, U. H. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:2:135 · Cited by 26
Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis
Rautiainen, H., Färkkilä, M. A., Neuvonen, M., Sane, T., Karvonen, A.-L., Nurmi, H., Kärkkäinen, P., Neuvonen, P. J., & Backman, J. T. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03155.x · Cited by 23
The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid
Leuschner, M., Holtmeier, J., Ackermann, H., & Leuschner, U. (2002) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200212000-00014 · Cited by 23
Self-citation
PRIMARY BILIARY CIRRHOSIS, PRIMARY SCLEROSING CHOLANGITIS, AND AUTOIMMUNE CHOLANGITIS
Sherlock, S. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70098-2 · Cited by 23
The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects
Ronca, V., Davies, S. P., Oo, Y. H., & Lleo, A. (2025) · Hepatology · doi:10.1097/hep.0000000000001225 · Cited by 22
Treatment of primary biliary cirrhosis
Poupon, R. Y., & Poupon, R. E. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0107 · Cited by 22
Cholangiocyte death in ductopenic cholestatic cholangiopathies: Mechanistic basis and emerging therapeutic strategies
Salas‐Silva, S., Nieves, A. S., López-Ramirez, J., Bucio, L., Gómez-Quiroz, L. E., Gutiérrez‐Ruíz, M. C., & Roma, M. G. (2019) · Life Sciences · doi:10.1016/j.lfs.2018.12.044 · Cited by 21
Update on pharmacotherapies for cholestatic liver disease
Ali, A. H., Tabibian, J. H., & Lindor, K. D. (2016) · Hepatology Communications · doi:10.1002/hep4.1013 · Cited by 21
Why Doesn’t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?
Molinaro, A., & Marschall, H. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0345-y · Cited by 19
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis
Ronca, V., Carbone, M., Bernuzzi, F., Malinverno, F., Mousa, H. S., Gershwin, M. E., & Invernizzi, P. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1391093 · Cited by 18
Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis
Roda, E., Azzaroli, F., Nigro, G., Piazza, F., Jaboli, F., Ferrara, F., Liva, S., Giovanelli, S., Miracolo, A., Colecchia, A., et al. (2002) · Digestive and Liver Disease · doi:10.1016/s1590-8658(02)80112-8 · Cited by 19
Management of osteoporosis in primary biliary cirrhosis
Wolfhagen, F. H. J., van Buuren, H. R., Vleggaar, F. P., & Schalm, S. W. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0108 · Cited by 17
A patient with primary biliary cirrhosis associated with autoimmune hemolytic anemia
Nakasone, H., Sakugawa, H., Fukuchi, J., Miyagi, T., Sugama, R., Hokama, A., Nakayoshi, T., Kawakami, Y., Yamashiro, T., Kinjo, F., et al. (2000) · Journal of Gastroenterology · doi:10.1007/s005350050338 · Cited by 17
Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review
Mago, S., & Wu, G. Y. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00036 · Cited by 18
Primary biliary cirrhosis and liver transplantation
Akamatsu (2012) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2012.v1.2.66 · Cited by 17
Effect of bezafibrate in the treatment of primary biliary cirrhosis
Kurihara, T., Furukawa, M., Tsuchiya, M., Akimoto, M., Ishiguro, H., Hashimoto, H., Niimi, A., Maeda, A., Shigemoto, M., & Yamasha, K. (2000) · Current Therapeutic Research · doi:10.1016/s0011-393x(00)88530-6 · Cited by 15
Case–Control Study on Prednisolone Combined With Ursodeoxycholic Acid and Azathioprine in Pure Primary Biliary Cirrhosis With High Levels of Immunoglobulin G and Transaminases
Fang, Y., Lv, D.-X., Jia, W. P., Li, ., Deng, Y., Wang, Y., Yu, M., & Wang, G. (2014) · Medicine · doi:10.1097/md.0000000000000104 · Cited by 14
Improving prognosis in primary biliary cholangitis – Therapeutic options and strategy
Harms, M. H., van Buuren, H. R., & van der Meer, A. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.004 · Cited by 14
Treatment of primary biliary cirrhosis
Szalay, F. (2001) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(01)00055-9 · Cited by 14
Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis
Levy, C., & Lindor, K. D. (2003) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-003-0010-0 · Cited by 13
Treatment of Primary Biliary Cirrhosis with Ursodeoxycholic Acid, Budesonide and Fibrates
Poupon, R. Y. (2011) · Digestive Diseases · doi:10.1159/000324139 · Cited by 13
Changes in titers of antimitochondrial and antinuclear antibodies during the course of primary biliary cirrhosis
Masuda, J., Omagari, K., Matsuo, I., Kinoshita, H., Sakimura, K., Hazama, H., Ohba, K., Isomoto, H., Murase, K., Murata, I., et al. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02377.x · Cited by 13
Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol†
Kaplan, M. M., & Poupon, R. Y. (2009) · Hepatology · doi:10.1002/hep.22831 · Cited by 13
Nuclear receptor ligands in therapy of cholestatic liver disease
Sturm, E. (2009) · Frontiers in bioscience · doi:10.2741/3529 · Cited by 12
Management of Primary Biliary Cirrhosis and Autoimmune Cholangitis
Angulo, P., & Lindor, K. D. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70011-8 · Cited by 14
Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis with unusual initial presentation as fulminant hepatic failure
Kayaçetin, E., Köklü, S., & Temuçin, T. K. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2003.09.023 · Cited by 12
Novel Therapies on Primary Biliary Cirrhosis
Czul, F., & Levy, C. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.08.006 · Cited by 10
Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management.
Schreibman, I. R., & Regev, A. (2006) · PubMed Central · Cited by 10
Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid
Parés, A. R. (2015) · Digestive Diseases · doi:10.1159/000440761 · Cited by 9
Primary biliary cirrhosis: specific treatment
Carithers, R. L. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00103-x · Cited by 9
Primary Biliary Cirrhosis
Heathcote, J. (2004) · Wiley eBooks · doi:10.1002/9780470987025.ch28 · Cited by 9
Prim�r bili�re Leberzirrhose und Overlap-Syndrome
Strassburg, C. P., & Manns, M. P. (2004) · Der Internist · doi:10.1007/s00108-003-1127-x · Cited by 8
Methylprednisolone Administration in Primary Biliary Cirrhosis Increases Cholic Acid Turnover, Synthesis, and Deoxycholate Concentration in Bile
Mazzella, G., Fusaroli, P., Pezzoli, A., Azzaroli, F., Mazzeo, C., Zambonin, L., Simoni, P., Festi, D., & Roda, E. (1999) · Digestive Diseases and Sciences · doi:10.1023/a:1026687022202 · Cited by 8
The phenotypic landscape of primary biliary cholangitis and autoimmune hepatitis variants
Bolis, F., Cazzaniga, G., Pagni, F., Invernizzi, P., Carbone, M., & Gerussi, A. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastrohep.2024.502225 · Cited by 8
Immunsuppressive Therapie der autoimmunen Lebererkankungen
Rambusch, E. G., & Manns, M. P. (1997) · Der Internist · doi:10.1007/s001080050069 · Cited by 5
T Cell Repertoire in Primary Biliary Cirrhosis: A Common T Cell Clone and Repertoire Change After Treatment
Okamoto, R., Yamamoto, K., Yabushita, K., Okano, N., Shimada, N., Matsumura, S., Mizuno, M., Higashi, T., & Tsuji, T. (2001) · Journal of Clinical Immunology · doi:10.1023/a:1010983325927 · Cited by 4
Therapie cholestatischer Lebererkrankungen
Gatzen, M., & Pausch, J. (2002) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-002-1139-7 · Cited by 3
Primary Biliary Cirrhosis
Talwalkar, J. A., & Lindor, K. D. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50046-2 · Cited by 4
Basic immunosuppressive drugs outside solid organ transplantation
Braun, F., & Behrend, M. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.3.267 · Cited by 3
Primary Biliary Cirrhosis
Sherlock, F. S., & BSc, J. D. (2001) · Wiley eBooks · doi:10.1002/9780470986820.ch14 · Cited by 3
Tubulointerstitial nephritis with IgM-positive plasma cells complicated by liver failure
Kudo, T., Nakazawa, D., Nishio, S., Hattanda, F., Ueda, Y., Yoshikawa, J., Shiratori‐Aso, S., Iwasaki, S., Tsuji, T., Nakanuma, Y., et al. (2024) · CEN Case Reports · doi:10.1007/s13730-024-00932-9 · Cited by 2
Cirrhose biliaire primitive
Poupon, R. Y. (2010) · EMC - Hépatologie · doi:10.1016/s1155-1976(10)46408-6 · Cited by 2
Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
Aquino, J. B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1792423 · Cited by 1
“…and 1996, two studies evaluated the administration of ursodeoxycholic acid (UDCA), a hydrophilic secondary bile acid , in patients with cystic ﬁ brosis – associated liver disease (200) and early-stage primary biliary cirrhosis (201), respectively, reporting modest improvements in liver function.”
Therapie cholestatischer Lebererkrankungen
Pausch, J., & Gatzen, M. (2006) · Der Internist · doi:10.1007/s00108-006-1732-6 · Cited by 1
Cirrosis biliar primaria
Poupon, R. Y. (2010) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(10)70489-x · Cited by 1
Cirrhose biliaire primitive
Poupon, R. Y. (2010) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(10)54652-0 · Cited by 2
Drug therapy of primary biliary diseases: classical and modern strategies
Schlichting, J., & Leuschner, U. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00144.x · Cited by 1
Self-citation
Multi-Omics Analysis Reveals Potential Therapeutic Targets and Genetic Mechanisms in Primary Biliary CholangitisPreprint
Chen, J., Lyu, Y., Huang, W., Li, Z., Yang, L., Yu, S., Zeng, R., Deng, Y., Liang, Z., Wang, J., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7186861/v1 · Cited by 1
Orphan drugs in development for primary biliary cirrhosis: challenges and progress
Lindor, K. D., Ali, A. H., & Byrne, T. (2015) · Orphan Drugs Research and Reviews · doi:10.2147/odrr.s69477
Primary Biliary Cirrhosis
Dancygier, H. (2009) · Springer eBooks · doi:10.1007/978-3-642-04519-6_19
Epidemiology and Treatment Options of Primary Biliary Cirrhosis
Rautiainen, H. (2008) · Työväentutkimus Vuosikirja

Authors: Leuschner, M., Güldütuna, S., You, T., Hübner, K., Bhatti, S., & Leuschner, U.
Affiliations: Goethe University Frankfurt (DE)
Corresponding author: Leuschner, Ulrich
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 1996-07
Volume: 25
Issue: 1
Pages: 49-57
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/s0168-8278(96)80327-8
OpenAlex: W2012146760
Cited by: 119
References: 33
Citations by year: 2026: 1 · 2025: 3 · 2024: 3 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 6 · 2013: 1 · 2012: 5
FWCI: 2.98
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: primary biliary cirrhosis, ursodeoxycholic acid, prednisolone, combination therapy, glucocorticoids, liver histopathology, IgG, cholestasis, serum bile acids, osteoporosis, early-stage disease
MeSH terms: Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunoglobulin G, Liver, Liver Cirrhosis, Biliary, Male, Middle Aged, Prednisolone, Prospective Studies, Ursodeoxycholic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks